Cross Country Healthcare (CCRN) Proxy filing summary

Voting matters and shareholder proposals

• Proposal 4 concerns the approval of an Amended Plan, with the Board's recommendation remaining in favor of the proposal.

• The supplement clarifies language under the “New Plan Benefits” section, replacing prior paragraphs to remove extraneous content.

Executive compensation and say-on-pay

• Future benefits under the Amended Plan will be granted at the discretion of the Committee and are not currently determinable.

• No awards have been previously granted that are contingent on the approval of the Amended Plan.

• The closing price of a Share on Nasdaq as of March 25, 2026, was $9.79.

Board of directors and corporate governance

• The Board's recommendation for Proposal 4 remains unchanged despite the supplement to the proxy statement.